BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics (TPST)Tempest TherapeuticsEarnings

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of

Open original release

Related news

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

View all latest news

Tempest Therapeutics

Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.

Recent company news

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-29 12:00 EST

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-22 12:00 EST

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Stock data

Close
0.93 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States